The present body of in vitro research indicates that polysulfobetaine-based core cross-linked micelles (CCMs) possess great potential as a treatment modality for HER2-positive breast cancer, as an alternative to PEG-based CCMs. This evidence concerns the gene ERBB2 and breast cancer.